Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome
-
Ying-Ying Zhang
and
Jun Qian
Abstract
Background:
DNMT3A is a DNA methyltransferase that acts in de novo methylation. Aberrant expression of DNMT3A has been reported in several human diseases, including myelodysplastic syndrome (MDS). However, the pattern of DNMT3A methylation remains unknown in MDS.
Methods:
The present study was aimed to investigate the methylation status of DNMT3A intragenic differentially methylated region 2 (DMR2) using real-time quantitative methylation-specific PCR and analyze its clinical significance in MDS.
Results:
Aberrant hypomethylation of DNMT3A was found in 57% (51/90) MDS cases. There were no significant differences in age, sex, white blood cell counts, platelet counts, hemoglobin counts and World Health Organization, International Prognostic Scoring System and karyotype classifications between DNMT3A hypomethylated and DNMT3A hypermethylated groups. However, the patients with DNMT3A hypomethylation had shorter overall survival time than those without DNMT3A hypomethylation (11 months vs. 36 months, p=0.033). Multivariate analysis confirmed the independent adverse impact of DNMT3A hypomethylation in MDS.
Conclusions:
Our data suggest that DNMT3A DMR2 hypomethylation may be a negative prognostic hallmark in MDS.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This work was supported by the National Natural Science foundation of China (81172592, 81270630), Special Funds of “Ke Jiao Qiang Wei” Project of Jiangsu Province, 333 Project of Jiangsu Province (BRA2016131), Six Talent Peaks Project in Jiangsu Province (2015-WSN-115), China Postdoctoral Science Foundation funded project (2016M601748), Social Development Foundation of Zhenjiang (SH2014044, SH2014086, SH2015058, SH2016045, SH2016046), Social Development Foundation of Kunshan (KS1624), Key Medical Talent Program of Zhenjiang City, Science and Technology Special Project in Clinical Medicine of Jiangsu Province (BL2012056) and Research and Development Foundation of Clinical Medicine of Jiangsu University (JLY20140018).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872–85.10.1056/NEJMra0902908Search in Google Scholar PubMed
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–51.10.1182/blood-2009-03-209262Search in Google Scholar PubMed
3. Wandt H, Haferlach T, Thiede C, Ehninger G. WHO classification of myeloid neoplasms and leukemia. Blood 2010;115:748–9.10.1182/blood-2009-10-249664Search in Google Scholar PubMed PubMed Central
4. Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008;113:3331–40.10.1002/cncr.23977Search in Google Scholar PubMed
5. Lai YY, Huang XJ, Li J, Zou P, Xu ZF, Sun H, et al. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China. Leuk Res 2015;39:530–5.10.1016/j.leukres.2015.02.005Search in Google Scholar PubMed
6. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496–506.10.1056/NEJMoa1013343Search in Google Scholar PubMed PubMed Central
7. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384–95.10.1056/NEJMoa1103283Search in Google Scholar PubMed PubMed Central
8. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25:1153–8.10.1038/leu.2011.44Search in Google Scholar PubMed PubMed Central
9. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2011;6:e26906.10.1371/journal.pone.0026906Search in Google Scholar PubMed PubMed Central
10. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012;44:53–7.10.1038/ng.1031Search in Google Scholar PubMed PubMed Central
11. Kang H, Wang X, Gao L, Cen J, Li M, Wang W, et al. Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome. Eur J Med Res 2015;20:16.10.1186/s40001-015-0092-xSearch in Google Scholar PubMed PubMed Central
12. Fan R, Zhao XL, Wang H, He HY, Peng ZP, Yang B, et al. Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome. Clin Lab 2014;60:1465–74.10.7754/Clin.Lab.2013.130414Search in Google Scholar
13. Chaubey R, Sazawal S, Mahapatra M, Chhikara S, Saxena R. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients. Int J Lab Hematol 2015;37:265–71.10.1111/ijlh.12283Search in Google Scholar PubMed
14. Calvo X, Nomdedeu M, Navarro A, Tejero R, Costa D, Munoz C, et al. High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. Leuk Res 2014;38:874–81.10.1016/j.leukres.2014.04.015Search in Google Scholar PubMed
15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88.10.1182/blood.V89.6.2079Search in Google Scholar
16. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–10.10.1200/JCO.2006.08.5696Search in Google Scholar PubMed
17. Kantarjian H, O’Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351–61.10.1002/cncr.23697Search in Google Scholar PubMed PubMed Central
18. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–65.10.1182/blood-2012-03-420489Search in Google Scholar PubMed PubMed Central
19. Lehmann U, Brakensiek K, Kreipe H. Role of epigenetic changes in hematological malignancies. Ann Hematol 2004;83:137–52.10.1007/s00277-003-0798-7Search in Google Scholar PubMed
20. Nolte F, Hofmann WK. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 2008;87:777–95.10.1007/s00277-008-0502-zSearch in Google Scholar PubMed
21. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999;27:2291–8.10.1093/nar/27.11.2291Search in Google Scholar PubMed PubMed Central
22. Chedin F. The DNMT3 family of mammalian de novo DNA methyltransferases. Prog Mol Biol Transl Sci 2011;101:255–85.10.1016/B978-0-12-387685-0.00007-XSearch in Google Scholar PubMed
23. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247–57.10.1016/S0092-8674(00)81656-6Search in Google Scholar PubMed
24. Jost E, Lin Q, Weidner CI, Wilop S, Hoffmann M, Walenda T, et al. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia 2014;28:1227–34.10.1038/leu.2013.362Search in Google Scholar PubMed PubMed Central
25. Zhang YY, Yao DM, Zhu XW, Zhou JD, Ma JC, Yang J, et al. DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia. Leuk Res 2015;39:1041–7.10.1016/j.leukres.2015.06.015Search in Google Scholar PubMed
26. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–99.10.1111/j.1365-2141.1982.tb08475.xSearch in Google Scholar
27. Qian J, Zhu ZH, Lin J, Ming Yao DM, Li Y, Yang J, et al. Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome. Br J Haematol 2011;154:153–5.10.1111/j.1365-2141.2011.08585.xSearch in Google Scholar PubMed
28. Qian J, Lin J, Qian W, Ma JC, Qian SX, Li Y, et al. Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. Leuk Res 2013;37: 765–8.10.1016/j.leukres.2013.03.014Search in Google Scholar PubMed
29. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012;91:519–25.10.1007/s00277-011-1352-7Search in Google Scholar PubMed
30. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6–21.10.1101/gad.947102Search in Google Scholar PubMed
31. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998;19:219–20.10.1038/890Search in Google Scholar PubMed
32. Ding WJ, Fang JY, Chen XY, Peng YS. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci 2008;53:2083–9.10.1007/s10620-007-0145-2Search in Google Scholar PubMed
33. Oh BK, Kim H, Park HJ, Shim YH, Choi J, Park C, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med 2007;20:65–73.10.3892/ijmm.20.1.65Search in Google Scholar
34. Daniel FI, Rivero ER, Modolo F, Lopes TG, Salum FG. Immunohistochemical expression of DNA methyltransferases 1, 3a and 3b in oral leukoplakias and squamous cell carcinomas. Arch Oral Biol 2010;55:1024–30.10.1016/j.archoralbio.2010.08.009Search in Google Scholar PubMed
35. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001;97:1172–9.10.1182/blood.V97.5.1172Search in Google Scholar PubMed
36. Deng T, Kuang Y, Wang L, Li J, Wang Z, Fei J. An essential role for DNA methyltransferase 3a in melanoma tumorigenesis. Biochem Biophys Res Commun 2009;387:611–6.10.1016/j.bbrc.2009.07.093Search in Google Scholar PubMed
37. Zhao Z, Wu Q, Cheng J, Qiu X, Zhang J, Fan H. Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell. J Biomed Biotechnol 2010;2010:737535.10.1155/2010/737535Search in Google Scholar PubMed PubMed Central
38. Celik H, Mallaney C, Kothari A, Ostrander EL, Eultgen E, Martens A, et al. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 2015;125:619–28.10.1182/blood-2014-08-594564Search in Google Scholar PubMed PubMed Central
©2018 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Editorial
- Analytical quality: an unfinished journey
- Reviews
- Update in diagnosis and management of primary aldosteronism
- Diagnosis biomarkers in acute intestinal ischemic injury: so close, yet so far
- Opinion Papers
- Irregular analytical errors in diagnostic testing – a novel concept
- A Black Swan in clinical laboratory practice: the analytical error due to interferences in immunoassay methods
- General Clinical Chemistry and Laboratory Medicine
- Reaching consensus on communication of critical laboratory results using a collective intelligence method
- Stability of routine biochemical analytes in whole blood and plasma/serum: focus on potassium stability from lithium heparin
- GFR estimation based on standardized creatinine and cystatin C: a European multicenter analysis in older adults
- Binding of bromocresol green and bromocresol purple to albumin in hemodialysis patients
- Interlaboratory variability of urinary iodine measurements
- The venous thromboembolic risk and the clot wave analysis: a useful relationship?
- Hematology and Coagulation
- Autovalidation and automation of the postanalytical phase of routine hematology and coagulation analyses in a university hospital laboratory
- Reference Values and Biological Variations
- Indirect method for validating transference of reference intervals
- Differences in levels of albumin, ALT, AST, γ-GT and creatinine in frail, moderately healthy and healthy elderly individuals
- Cancer Diagnostics
- Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma
- Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome
- Cardiovascular Diseases
- Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin I
- MEF2C loss-of-function mutation associated with familial dilated cardiomyopathy
- Letter to the Editor
- Hyperuricemia does not seem to be an independent risk factor for coronary heart disease
- Reply to: Hyperuricemia does not seem to be an independent risk factor for coronary heart disease
- Preanalytics of ammonia: stability, transport and temperature of centrifugation
- Influence of delayed separation of plasma from whole blood on Cu, I, Mn, Se, and Zn plasma concentrations
- Copeptin as a diagnostic and prognostic biomarker in patients admitted to Emergency Department with syncope, presyncope and vertiginous syndrome
- Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood
- Selective changes in cholesterol metabolite levels in plasma of breast cancer patients after tumor removal
- Athletes beware before throwing towels to audiences
Articles in the same Issue
- Frontmatter
- Editorial
- Analytical quality: an unfinished journey
- Reviews
- Update in diagnosis and management of primary aldosteronism
- Diagnosis biomarkers in acute intestinal ischemic injury: so close, yet so far
- Opinion Papers
- Irregular analytical errors in diagnostic testing – a novel concept
- A Black Swan in clinical laboratory practice: the analytical error due to interferences in immunoassay methods
- General Clinical Chemistry and Laboratory Medicine
- Reaching consensus on communication of critical laboratory results using a collective intelligence method
- Stability of routine biochemical analytes in whole blood and plasma/serum: focus on potassium stability from lithium heparin
- GFR estimation based on standardized creatinine and cystatin C: a European multicenter analysis in older adults
- Binding of bromocresol green and bromocresol purple to albumin in hemodialysis patients
- Interlaboratory variability of urinary iodine measurements
- The venous thromboembolic risk and the clot wave analysis: a useful relationship?
- Hematology and Coagulation
- Autovalidation and automation of the postanalytical phase of routine hematology and coagulation analyses in a university hospital laboratory
- Reference Values and Biological Variations
- Indirect method for validating transference of reference intervals
- Differences in levels of albumin, ALT, AST, γ-GT and creatinine in frail, moderately healthy and healthy elderly individuals
- Cancer Diagnostics
- Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma
- Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome
- Cardiovascular Diseases
- Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin I
- MEF2C loss-of-function mutation associated with familial dilated cardiomyopathy
- Letter to the Editor
- Hyperuricemia does not seem to be an independent risk factor for coronary heart disease
- Reply to: Hyperuricemia does not seem to be an independent risk factor for coronary heart disease
- Preanalytics of ammonia: stability, transport and temperature of centrifugation
- Influence of delayed separation of plasma from whole blood on Cu, I, Mn, Se, and Zn plasma concentrations
- Copeptin as a diagnostic and prognostic biomarker in patients admitted to Emergency Department with syncope, presyncope and vertiginous syndrome
- Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood
- Selective changes in cholesterol metabolite levels in plasma of breast cancer patients after tumor removal
- Athletes beware before throwing towels to audiences
